Plasma Derived Therapy Market Size, Share, Growth, and Industry Analysis, By Type (Immunoglobulin, Coagulation factors, Albumin, Others), By Application (Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, Others), Regional Insights and Forecast to 2035

Plasma Derived Therapy Market Overview

The global Plasma Derived Therapy Market size estimated at USD 14509.96 million in 2026 and is projected to reach USD 19927.48 million by 2035, growing at a CAGR of 3.59% from 2026 to 2035.

The Plasma Derived Therapy Market is witnessing substantial expansion due to increasing demand for immunoglobulins, albumin, coagulation factors, and alpha-1 antitrypsin therapies across hospitals, specialty clinics, and biopharmaceutical facilities. More than 38 million liters of plasma are collected globally every year, supporting the treatment of over 80 rare and chronic disorders. Increasing prevalence of hemophilia, primary immunodeficiency diseases, liver disorders, and neurological conditions is accelerating Plasma Derived Therapy Market Growth. 

The United States dominates the Plasma Derived Therapy Market Share with over 70% of global plasma collection activities conducted across more than 1,000 plasma donation centers nationwide. Approximately 125,000 patients in the U.S. receive plasma-derived therapies annually for immune deficiencies and bleeding disorders. Rising prevalence of chronic inflammatory demyelinating polyneuropathy and hereditary angioedema continues to strengthen Plasma Derived Therapy Market Demand. More than 60% of immunoglobulin therapies administered globally originate from U.S.-sourced plasma. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Immunoglobulin demand increased by 19%, plasma donations rose by 14%, rare disease diagnosis improved by 22%, neurological therapy utilization expanded by 17%, and hospital-based plasma therapy administration increased by 16% globally.
• Major Market Restraint: Plasma collection costs increased by 13%, donor screening expenses rose by 11%, therapy processing delays expanded by 9%, supply shortages affected 15% of treatment centers, and regulatory compliance expenditures increased by 12% worldwide.
• Emerging Trends: Subcutaneous immunoglobulin adoption grew by 21%, home infusion therapy utilization increased by 18%, AI-based plasma screening integration rose by 16%, personalized plasma therapies expanded by 14%, and recombinant combination therapies increased by 12% globally.
• Regional Leadership: North America accounted for 48% market share, Europe contributed 27%, Asia-Pacific represented 19%, Latin America held 4%, and Middle East & Africa captured approximately 2% of Plasma Derived Therapy Market Share.
• Competitive Landscape: Top five manufacturers controlled nearly 68% of global plasma fractionation capacity, while strategic collaborations increased by 24%, production facility expansions rose by 17%, and plasma center acquisitions expanded by 15% globally.
• Market Segmentation: Immunoglobulins represented 45% of total applications, albumin therapies accounted for 23%, coagulation factors contributed 19%, alpha-1 antitrypsin therapies captured 8%, and hyperimmune globulins held approximately 5% share worldwide.
• Recent Development: Plasma collection center expansions increased by 20%, biologics manufacturing investments rose by 18%, advanced purification technology adoption grew by 16%, FDA approvals expanded by 11%, and rare disease treatment programs increased by 14% globally.

Plasma Derived Therapy Market Latest Trends

The Plasma Derived Therapy Market Trends are increasingly influenced by growing utilization of immunoglobulin therapies in neurological and autoimmune disease treatment. More than 50% of plasma-derived products are currently used in immunology-related applications, with demand for intravenous immunoglobulin therapies increasing significantly across developed healthcare systems. Hospitals and specialty treatment centers are reporting a 20% increase in chronic inflammatory demyelinating polyneuropathy therapy administration. Home-based infusion therapy adoption has increased by nearly 18%, improving patient convenience while reducing hospital dependency. Plasma Derived Therapy Market Research Report findings indicate that digital donor management systems and automated plasma screening technologies are improving donor retention rates by approximately 15% globally.

The Plasma Derived Therapy Market Insights further reveal growing investments in plasma fractionation technologies and biologics manufacturing capacity expansion. More than 70 new plasma collection centers were established globally within the past two years to address supply-demand gaps. Asia-Pacific countries are increasing plasma therapy imports by nearly 22% due to rising diagnosis of hemophilia and immune deficiencies. Demand for subcutaneous immunoglobulin products increased by approximately 21% because of improved patient compliance and reduced infusion complications. 

Plasma Derived Therapy Market Dynamics

DRIVER

"Rising prevalence of immune deficiency and bleeding disorders"

The increasing incidence of primary immunodeficiency diseases, hemophilia, neurological disorders, and liver-related complications remains the primary growth driver for the Plasma Derived Therapy Market. More than 400 hereditary bleeding disorders have been identified globally, while over 6 million individuals are estimated to suffer from immune deficiency conditions requiring plasma-derived therapies. Utilization of immunoglobulin products increased by approximately 19% across hospitals and specialty clinics. Hemophilia treatment demand expanded by nearly 16% due to improved diagnosis programs and patient awareness initiatives. 

RESTRAINTS

"Limited plasma supply and high processing complexity"

One of the major restraints affecting the Plasma Derived Therapy Market is the limited availability of human plasma and the complex biological processing requirements involved in plasma fractionation. Nearly 15% of treatment facilities globally experience periodic plasma shortages affecting therapy continuity. Plasma collection and donor screening operations involve stringent regulatory compliance standards, increasing operational costs by approximately 13%.

OPPORTUNITY

"Expansion of advanced plasma collection infrastructure"

Growing investments in plasma donation centers and biopharmaceutical manufacturing facilities are creating substantial Plasma Derived Therapy Market Opportunities. More than 100 new plasma collection projects have been announced globally to improve plasma availability and support rising therapeutic demand. Automated plasmapheresis systems increased collection efficiency by approximately 17%, reducing donor processing times significantly. Asia-Pacific healthcare providers are increasing investment in plasma therapy infrastructure due to growing patient populations and increasing diagnosis rates for rare diseases. 

CHALLENGE

"Stringent regulatory approvals and treatment accessibility issues"

The Plasma Derived Therapy Market faces significant challenges associated with strict regulatory frameworks, high therapy costs, and uneven global access to advanced biologics. More than 30% of developing countries continue to depend heavily on imported plasma-derived medicinal products due to limited domestic fractionation capabilities. Regulatory approval timelines for plasma-derived therapies often exceed several years because of rigorous safety and viral inactivation requirements.

Plasma Derived Therapy Market Segmentation

The Plasma Derived Therapy Market is segmented by type and application based on therapeutic usage, plasma protein concentration, disease prevalence, and healthcare adoption patterns. By type, immunoglobulin therapies dominate due to increasing utilization in neurological and immunological disorders, while coagulation factors remain essential in hemophilia treatment. Albumin therapies are witnessing growing adoption in liver disease and trauma care management. By application, hemophilia and primary immunodeficiency diseases account for significant treatment demand due to rising diagnosis rates and increasing plasma-derived therapy administration across hospitals and specialty healthcare centers globally.

Download Free Sample to learn more about this report.

BY TYPE

Immunoglobulin: Immunoglobulin therapies represent the largest segment within the Plasma Derived Therapy Market due to rising demand for immune deficiency treatment and neurological disease management. More than 45% of plasma-derived medicinal products are associated with immunoglobulin applications globally. Intravenous immunoglobulin therapies are widely administered in hospitals, specialty infusion centers, and home healthcare environments for treating chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, Guillain-Barré syndrome, and primary immunodeficiency disorders. More than 6 million individuals globally are estimated to suffer from immune deficiency conditions requiring long-term immunoglobulin support. Utilization of subcutaneous immunoglobulin therapies increased by nearly 21% because of improved patient compliance and reduced hospitalization dependency. More than 50 approved immunoglobulin formulations are commercially distributed worldwide, supporting expanding therapeutic accessibility. 

Coagulation Factors: Coagulation factors represent a critical segment of the Plasma Derived Therapy Market because of increasing demand for hemophilia treatment and bleeding disorder management. More than 400 hereditary bleeding disorders have been identified globally, with hemophilia A and hemophilia B accounting for a significant share of plasma-derived coagulation therapy utilization. Approximately 70% of severe hemophilia patients require regular prophylactic treatment involving plasma-derived or recombinant clotting factor concentrates. Factor VIII and Factor IX therapies remain essential components of hospital-based hematology treatment programs. Plasma-derived coagulation products continue to maintain strong demand due to their effectiveness in controlling spontaneous bleeding episodes and surgical bleeding complications.

Albumin: Albumin therapies hold a substantial position in the Plasma Derived Therapy Market because of their widespread utilization in trauma care, liver disease management, cardiovascular surgery, and critical care treatment procedures. Albumin contributes approximately 23% of plasma-derived therapy applications worldwide and remains one of the most frequently administered plasma proteins in intensive care settings. More than 50% of albumin utilization is associated with liver cirrhosis, hypoalbuminemia, severe burns, and septic shock management. Hospitals increasingly utilize albumin during emergency surgical interventions and fluid replacement therapies because of its role in maintaining plasma osmotic pressure and circulatory stability. More than 10 million liver disease patients globally require supportive albumin-based treatment procedures annually. 

Others: The “Others” segment in the Plasma Derived Therapy Market includes alpha-1 antitrypsin therapies, hyperimmune globulins, fibrin sealants, and specialty plasma proteins used in rare disease treatment applications. Alpha-1 antitrypsin deficiency affects approximately 1 in 2,500 individuals in several developed healthcare regions, contributing to growing demand for plasma-derived augmentation therapies. Hyperimmune globulin therapies are increasingly utilized for infectious disease prevention and immune response management in immunocompromised patients. Specialty plasma proteins are also used in burn care management, respiratory disease treatment, and surgical wound healing procedures. More than 8% of total plasma-derived therapy demand is associated with alpha-1 antitrypsin applications globally. 

BY APPLICATION

Hemophilia: Hemophilia remains one of the leading application segments in the Plasma Derived Therapy Market due to increasing prevalence of hereditary bleeding disorders and growing utilization of plasma-derived coagulation factors. More than 300,000 individuals globally are estimated to suffer from hemophilia-related conditions, including hemophilia A and hemophilia B. Severe hemophilia patients experience spontaneous bleeding episodes requiring regular prophylactic clotting factor administration to prevent joint damage and internal hemorrhage complications. Plasma-derived Factor VIII and Factor IX therapies remain widely utilized in hematology treatment centers and specialized hospitals globally. Approximately 70% of severe hemophilia patients receive long-term coagulation factor replacement therapy. Increased awareness campaigns and improved newborn screening programs are contributing to earlier diagnosis and increased treatment adoption. 

Primary Immunodeficiency Disease: Primary immunodeficiency disease represents a major application area in the Plasma Derived Therapy Market due to rising diagnosis rates and increasing demand for immunoglobulin replacement therapies. More than 6 million individuals globally are estimated to suffer from primary immunodeficiency conditions, while only a fraction receive early clinical diagnosis. Plasma-derived immunoglobulin therapies remain the standard treatment approach for preventing recurrent infections and improving immune system functionality in affected patients. Hospitals and specialty infusion centers are reporting increased administration of intravenous and subcutaneous immunoglobulin products across pediatric and adult patient populations. Demand for subcutaneous immunoglobulin therapy increased by approximately 21% because of improved patient convenience and reduced hospital dependency.

Idiopathic Thrombocytopenic Purpura: Idiopathic thrombocytopenic purpura is an important application segment in the Plasma Derived Therapy Market because plasma-derived immunoglobulin therapies are widely used for platelet count stabilization and immune response management. The condition affects both pediatric and adult populations and is characterized by immune-mediated platelet destruction leading to bleeding complications. Intravenous immunoglobulin therapy is frequently administered in acute bleeding episodes and severe platelet deficiency cases. Healthcare providers reported approximately 16% growth in immunoglobulin utilization for hematological autoimmune disorders within specialty hospitals. More than 40% of severe immune thrombocytopenia patients receive immunoglobulin-based therapy during emergency treatment procedures. 

Others: The “Others” application segment within the Plasma Derived Therapy Market includes neurological disorders, liver disease management, respiratory disorders, trauma care, infectious disease prevention, and surgical applications. Plasma-derived therapies are increasingly utilized in chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, hereditary angioedema, and alpha-1 antitrypsin deficiency treatment programs. Neurological therapy applications increased by approximately 20% across hospitals and specialty infusion centers due to rising autoimmune disease diagnosis rates. More than 10 million liver disease patients globally receive supportive plasma protein therapies for hypoalbuminemia and circulatory stabilization procedures. Trauma care centers increasingly utilize albumin and fibrin sealants during emergency surgical interventions and critical care management. 

Plasma Derived Therapy Market Regional Outlook

The Plasma Derived Therapy Market demonstrates strong regional diversification supported by plasma collection infrastructure, healthcare accessibility, rare disease diagnosis rates, and biologics manufacturing capabilities. North America holds approximately 48% of global market share due to extensive plasma donation networks and advanced therapeutic adoption. Europe contributes nearly 27% market share with strong hematology and immunology treatment programs. Asia-Pacific accounts for around 19% share owing to expanding healthcare infrastructure and increasing diagnosis of immune disorders and hemophilia cases. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Plasma Derived Therapy Market with approximately 48% global market share due to extensive plasma collection infrastructure, advanced healthcare systems, and strong adoption of plasma-derived medicinal products. The United States alone contributes more than 70% of worldwide plasma collection volumes through over 1,000 plasma donation centers operating across major metropolitan and regional healthcare locations. More than 125,000 patients in North America receive plasma-derived therapies annually for hemophilia, immune deficiencies, neurological disorders, and autoimmune diseases. Immunoglobulin products account for nearly 46% of total plasma-derived therapy utilization across hospitals and specialty clinics within the region. Regulatory support for biologics manufacturing and ongoing investments in plasma collection expansion continue strengthening Plasma Derived Therapy Market Outlook across North America. More than 20 new plasma collection center projects were initiated recently to improve therapeutic plasma availability. Increasing adoption of advanced pathogen reduction technologies and automated plasmapheresis systems is improving production efficiency by approximately 17%. 

EUROPE

Europe accounts for nearly 27% of the global Plasma Derived Therapy Market Share due to increasing demand for immunoglobulin therapies, coagulation factors, and albumin products across public healthcare systems and specialty hospitals. Countries including Germany, France, Italy, Spain, and the United Kingdom maintain strong plasma therapy adoption rates because of advanced hematology and immunology treatment infrastructure. More than 90 million plasma-derived therapy doses are administered annually across Europe for treating primary immunodeficiency diseases, neurological disorders, and bleeding conditions. Plasma Derived Therapy Market Trends in Europe are further shaped by growing investments in plasma purification technologies and biologics safety improvements. More than 40 plasma fractionation facilities are actively operating across the region to address rising demand for plasma proteins and specialty biologics. Advanced pathogen reduction systems improved plasma product safety efficiency by nearly 14% across major European manufacturing facilities. 

GERMANY Plasma Derived Therapy Market

Germany represents one of the most advanced healthcare markets within the European Plasma Derived Therapy Market, accounting for approximately 22% of the regional market share. The country maintains a strong biologics manufacturing base supported by advanced plasma fractionation technologies and extensive hospital treatment infrastructure. More than 6,000 patients in Germany receive plasma-derived coagulation therapies for hemophilia and hereditary bleeding disorders annually. Immunoglobulin therapies are increasingly utilized across neurology and immunology departments due to growing autoimmune disease prevalence. Healthcare providers across Germany reported nearly 17% growth in intravenous immunoglobulin utilization for chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome treatment applications. More than 40% of plasma-derived therapy demand in Germany is associated with immune deficiency disease management. Plasma donation awareness initiatives and advanced donor screening systems improved collection efficiency by approximately 13%. 

UNITED KINGDOM Plasma Derived Therapy Market

The United Kingdom contributes approximately 18% of the Europe Plasma Derived Therapy Market Share due to increasing demand for immunoglobulin therapies and coagulation factor concentrates across public healthcare institutions and specialty treatment centers. More than 12,000 patients in the UK receive plasma-derived therapies annually for primary immunodeficiency disorders, hemophilia, and neurological diseases. The National Health Service continues expanding biologics treatment accessibility for autoimmune and rare disease patients. Hospitals across the United Kingdom reported approximately 15% growth in immunoglobulin therapy administration due to rising neurological disorder diagnosis rates. More than 45% of plasma-derived medicinal products utilized in the country are associated with immunology and autoimmune disease treatment applications. Plasma-derived albumin therapies are increasingly administered within emergency care units and intensive care facilities for liver disease and trauma management procedures.

ASIA-PACIFIC

Asia-Pacific represents approximately 19% of the global Plasma Derived Therapy Market Share due to expanding healthcare infrastructure, increasing plasma therapy awareness, and rising prevalence of rare diseases and immune disorders. Countries including China, Japan, India, South Korea, and Australia are experiencing growing demand for immunoglobulin therapies, coagulation factors, and albumin products across hospitals and specialty healthcare facilities. Plasma therapy imports across Asia-Pacific increased by nearly 22% because of rising patient diagnosis rates and expanding biologics accessibility. Plasma Derived Therapy Market Trends across Asia-Pacific are also influenced by growing pharmaceutical manufacturing investments and increasing adoption of automated plasmapheresis technologies. Advanced purification systems improved plasma protein recovery efficiency by nearly 12% across regional manufacturing facilities. Governments continue expanding rare disease treatment reimbursement programs and biologics accessibility initiatives. 

JAPAN Plasma Derived Therapy Market

Japan accounts for approximately 28% of the Asia-Pacific Plasma Derived Therapy Market Share due to advanced healthcare infrastructure, strong biologics adoption, and increasing prevalence of neurological and autoimmune diseases. More than 20,000 patients in Japan receive plasma-derived therapies annually for immune deficiencies, hereditary bleeding disorders, and chronic neurological conditions. Intravenous immunoglobulin therapies are extensively utilized within specialty hospitals and neurology treatment centers. Japanese healthcare providers reported nearly 16% growth in plasma-derived immunoglobulin administration procedures due to rising diagnosis of chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome. More than 40% of plasma-derived medicinal products utilized in Japan are associated with immunology and neurological treatment applications. Plasma-derived albumin therapies are also increasingly used in liver disease management and critical care procedures.

CHINA Plasma Derived Therapy Market

China represents one of the fastest-growing healthcare markets within the Asia-Pacific Plasma Derived Therapy Market and contributes approximately 34% of regional market share. Rising prevalence of liver diseases, immune disorders, and hereditary bleeding conditions continues increasing demand for plasma-derived medicinal products across hospitals and specialty treatment centers. More than 100 plasma collection facilities are actively operating throughout China to support increasing biologics demand. Chinese hospitals reported approximately 21% growth in albumin therapy administration due to increasing hospitalization rates and expansion of critical care infrastructure. Plasma-derived immunoglobulin utilization also increased significantly because of improved diagnosis rates for autoimmune and neurological disorders. More than 30% of plasma-derived therapies in China are associated with emergency medicine and liver disease treatment applications.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 6% of the global Plasma Derived Therapy Market Share due to improving healthcare infrastructure, increasing biologics accessibility, and rising diagnosis rates for immune deficiencies and bleeding disorders. Countries including Saudi Arabia, the United Arab Emirates, South Africa, and Egypt are witnessing growing demand for plasma-derived medicinal products across hospitals and specialty healthcare centers. Plasma-derived immunoglobulin therapies remain the most widely utilized treatment category within the region. South Africa remains one of the largest plasma-derived therapy consumers within Africa due to advanced healthcare infrastructure and expanding rare disease treatment programs. Increasing utilization of plasma-derived coagulation factors and immunoglobulin products continues strengthening Plasma Derived Therapy Market Growth across regional healthcare systems. 

List of Key Plasma Derived Therapy Market Companies

• CSL Behring
• Takeda Pharmaceutical Company Limited
• BPL
• ADMA Biologics
• Biotest AG
• Octapharma
• Grifols
• Kamada Pharmaceuticals
• SK Plasma
• SA
• Kedrion
• Pfizer

Top Two Companies with Highest Share

• CSL Behring: Holds approximately 28% market share supported by extensive plasma collection operations, advanced immunoglobulin manufacturing, and strong global biologics distribution capabilities.
• Grifols: Accounts for nearly 24% market share driven by large-scale plasma fractionation infrastructure, strong albumin production capacity, and expanding specialty plasma therapy portfolio.

Investment Analysis and Opportunities

The Plasma Derived Therapy Market continues attracting substantial investments due to increasing demand for plasma-derived medicinal products, growing rare disease diagnosis rates, and expansion of biologics manufacturing infrastructure. More than 100 plasma collection center projects have been announced globally to improve plasma availability and strengthen supply chain efficiency. Automated plasmapheresis technologies improved plasma collection productivity by approximately 17%, encouraging healthcare providers and pharmaceutical manufacturers to expand donor recruitment programs. Investments in advanced plasma purification systems increased by nearly 16% due to rising demand for high-purity immunoglobulin and coagulation factor therapies.

Asia-Pacific and Middle East healthcare markets are witnessing increasing biologics infrastructure investments because of expanding healthcare accessibility and rising plasma therapy imports. Plasma fractionation facilities are integrating advanced pathogen reduction technologies that improved biologics safety efficiency by nearly 14%. Growing adoption of home-based infusion therapies and subcutaneous immunoglobulin products is creating new Plasma Derived Therapy Market Opportunities within outpatient treatment environments. Healthcare providers are also increasing investments in digital donor management systems and AI-based plasma screening platforms, improving donor retention rates by approximately 15% while strengthening long-term plasma supply sustainability.

New Products Development

The Plasma Derived Therapy Market is witnessing continuous development of advanced plasma-derived medicinal products focused on improved patient compliance, enhanced therapeutic efficacy, and reduced infusion complications. Demand for subcutaneous immunoglobulin formulations increased by approximately 21% due to improved convenience and reduced hospitalization requirements. Pharmaceutical manufacturers are expanding research involving recombinant-plasma hybrid therapies to improve treatment outcomes in neurological disorders, immune deficiencies, and hematological conditions.

Advanced purification technologies improved plasma protein recovery efficiency by nearly 12%, supporting development of next-generation coagulation factor concentrates and specialty biologics. More than 25% of recently introduced plasma-derived therapies focus on rare disease treatment applications involving hereditary angioedema, alpha-1 antitrypsin deficiency, and autoimmune neurological disorders. Manufacturers are also developing high-concentration albumin products for trauma care and critical care management. Increased integration of viral inactivation systems and biologics safety enhancements continues improving therapeutic reliability across plasma-derived product portfolios globally.

Five Recent Developments

• CSL Behring expanded plasma collection operations by approximately 18% through new donor center openings and integration of automated plasmapheresis technologies to strengthen immunoglobulin and coagulation factor production capacity across multiple healthcare markets.
• Takeda Pharmaceutical Company Limited increased production efficiency by nearly 15% after upgrading plasma purification systems and enhancing biologics manufacturing infrastructure focused on immunoglobulin therapies for neurological and immune deficiency treatment applications.
• Grifols implemented advanced pathogen reduction technologies that improved plasma protein safety standards by approximately 14%, while simultaneously increasing albumin and immunoglobulin processing capabilities across several fractionation facilities.
• Octapharma expanded subcutaneous immunoglobulin therapy programs by nearly 16% to support growing home-based infusion demand and improve patient accessibility for chronic immune deficiency and autoimmune disorder treatment procedures.
• ADMA Biologics strengthened plasma donor recruitment programs, resulting in approximately 13% growth in plasma collection volumes while improving specialty immunoglobulin product availability across hospitals and specialty healthcare providers.

Report Coverage Of Plasma Derived Therapy Market

The Plasma Derived Therapy Market Report provides extensive analysis of plasma-derived medicinal products, therapeutic applications, biologics manufacturing trends, and regional healthcare developments across major global markets. The report evaluates plasma collection infrastructure, immunoglobulin utilization patterns, coagulation factor demand, albumin therapy adoption, and specialty plasma protein applications within hospitals, specialty clinics, and critical care facilities. More than 45% of total market demand is associated with immunoglobulin therapies, while coagulation factors and albumin therapies continue demonstrating strong treatment adoption across hematology and emergency medicine applications.

The report further examines Plasma Derived Therapy Market Trends involving automated plasmapheresis systems, advanced purification technologies, pathogen reduction innovations, and home-based infusion therapy expansion. North America maintains approximately 48% market share due to advanced plasma collection networks and biologics manufacturing capabilities, while Asia-Pacific continues experiencing strong healthcare infrastructure expansion and increasing plasma therapy imports.